The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
The new assay consolidates screening for four major viral threats into a single workflow
Subscribe To Our Newsletter & Stay Updated
